

# Ali-Reza Golshayan, MD

Medical University of South Carolina  
96 Jonathan Lucas St, Suite 903  
Charleston, SC 29425  
Tel: (843) 792-4271  
Fax: (843) 792-0644  
Email: [golshaya@musc.edu](mailto:golshaya@musc.edu)

---

## **Education and Training:**

Bachelor of Arts:	Tufts University Medford, MA (1991 – 1995)
Medical Degree:	University of Vermont, College of Medicine Burlington, VT (1996 – 2001)
Internship, Internal Medicine:	Cleveland Clinic Foundation Cleveland, OH (7/2001 – 6/2002)
Residency, Internal Medicine:	Cleveland Clinic Foundation Cleveland, OH (7/2002 – 6/2004)
Fellowship, Hematology/Oncology:	Cleveland Clinic, Taussig Cancer Institute Cleveland, OH (7/2004 – 6/2007)
Fellowship, Experimental Therapeutics:	Cleveland Clinic, Taussig Cancer Institute Cleveland, OH (7/2007 – 6/2008)

## **Speciality / Board Certification:**

American Board of Internal Medicine (2004)  
Medical Oncology (anticipated 2009)

## **Licensure:**

South Carolina (7/2008 – present)

### **Academic Appointments:**

Assistant Professor of Medicine  
Medical University of South Carolina, Charleston SC (7/2008 – present)

### **Professional Activities:**

Fellowship Research Advisor (8/2008 – present)

MUSC Second Year Medical Student Physical Examination instructor (8/2008 – present)

Ad Hoc Manuscript Reviewer for peer-reviewed journals (Cancer, Journal of Urology, Clinical Genitourinary Cancer) (7/2008 – present)

### **Professional Organizations:**

American Medical Association  
American Society of Clinical Oncology  
Southwest Oncology Group

### **Awards:**

Freeman Medical Scholar (2000, 2001)

David M. Tormey Award “perseverance in the pursuit of a medical education” (2001)

### **Research:**

#### ***Publications***

1. Rossillo A, Verma A, Saad EB, Corrado A, Gasparini G, Marrouche N, **Golshayan AR**, McCurdy R, Bhargava M, Khaykin Y, Burkhardt JD, Martin DO, Wilkoff BL, Saliba WI, Schweikert RA, Raviele A, Natale A. Impact of Coronary Sinus Lead Position on Biventricular Pacing - Mortality and Echocardiographic Evaluation During Long-Term Follow-Up. *J Cardiovasc Electrophysiol* 2004 Oct 15(10):1120-1125.
2. Sekeres MA, Fu AZ, Jaroslaw Maciejewski JP, **Golshayan AR**, Matt E, Kalaycio MW, Kattan MW. A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. *Cancer*. 2007 Mar 15;109(6):1125-32

3. **Golshayan AR**, Jin T, Maciejewski J, Fu AZ, Bershadsky B, Kattan MW, Kalaycio ME, Sekeres MA. Efficacy of Growth Factors compared to other therapies for Low-Risk Myelodysplastic Syndromes. *Br J Haematol*. 2007 Apr;137(2):125-32.
4. Choueiri TK, Garcia JA, Elson O, Khasawneh M, Usman S, **Golshayan AR**, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. *Cancer*. 2007 Jun 18;110(3):543-550
5. **Golshayan AR** and Bukowski RM. Is temsirolimus more safe and effective than interferon  $\alpha$  for the treatment of advanced renal cell carcinoma? Practice Point Commentary. *Nat Clin Pract Urol*. 2007 Sep 4; [Epub ahead of print]
6. **Golshayan AR**, Brick AJ, Choueiri TK. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. *Future Oncol*. 2008 Feb;4(1):85-92
7. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, **Golshayan AR**, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. Von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma. *J Urol*. 2008 Sep;180(3):860-5.
8. J. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, **A. Golshayan**, L. Wood, P. Elson, J. Garcia, R. Dreicer, R. Bukowski. Sunitinib Reverses Type 1 Immune Suppression and Decreases T Regulatory Cells in Renal Cell Carcinoma Patients. *Clin Cancer Res*. 2008 Oct 15;14(20):6674-82.
9. **AR Golshayan**, RM Bukowski. The role of sunitinib in metastatic renal cell carcinoma. *Hot Topics in Oncology*. 2008; Issue 4.
10. **Golshayan, AR**; George, S; Heng, D; Elson, P; Wood, L; Mekhail, T; Garcia, JA; Aydin, H; Zhou; Bukowski, R. Metastatic Sarcomatoid Renal Cell Carcinoma Treated With VEGF-targeted Therapy. *Journal of Clinical Oncology*. 2009 Jan 10; 27:235-241.
11. DYC Heng, WL Xie, MM Regan, MA Warren, **AR Golshayan**, C Sahi, BJ Eigl, JD Reuther, T Cheng, S North, P Venner, JJ Knox, KN Chi, C Kollmannsberger, DF McDermott, WK Oh, MB Atkins, RM Bukowski, BI Rini, TK Choueiri. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. Submitted to *Journal of Clinical Oncology* February 2009.

## ***Posters & Presentations***

1. Somerville J, **Golshayan A**. Complex pulmonary atresia following radical repair. Long term costs of health care. Oral Presentation. American College of Cardiology 10<sup>th</sup> International Symposium on Congenital Heart disease in the Adult. Toronto, Canada, July 1999.
2. Mikkael A. Sekeres, Alex Z. Fu, Jaroslaw P. Maciejewski, **Ali-Reza Golshayan**, Matt Kalaycio, Michael W. Kattan . A Decision Analysis to Determine the Appropriate Treatment for Low-Risk Myelodysplastic Syndromes. 2005 ASH Annual Meeting. Blood. Volume 106, issue 11, November 16, 2005, Abstract #2533 [Poster Presentation]
3. **A. Golshayan**, A. Z. Fu, M. W. Kattan, S. Brown, J. P. Maciejewski, M. A. Sekeres Efficacy of Growth Factors Compared to Chemotherapy in Low-Risk Myelodysplastic Syndromes. 2005 ASH Annual Meeting. Blood. Volume 106, issue 11, November 16, 2005, Abstract #2540. [Poster Presentation]
4. T.K. Choueiri, J.A. Garcia, B.I. Rini, S. Usman, M. Khasawneh, **A. Golshayan**, L. Wood, P. Elson and R.M. Bukowski. Clinical Prognostic Factors in Metastatic RCC Patients Treated with Anti-VEGF therapy. The Fifth International Kidney Cancer Symposium. September 23, 2006. [Oral Presentation]
5. **A. Golshayan**, T. K. Choueiri, P. Elson, J. A. Garcia, M. Khaswneh, S. Usman, I. Tamaskar, L. Wood, B. I. Rini, R. M. Bukowski. Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy. Journal of Clinical Oncology. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5046 [Poster Discussion]
6. **A. R. Golshayan**, T. K. Choueiri, D. Heng, S. George, L. Wood, J. A. Garcia, B. I. Rini, R. M. Bukowski. Survival update of risk group definitions associated with outcome in metastatic renal cell carcinoma (RCC) patients treated with VEGF-targeted therapy. The Sixth International Kidney Cancer Symposium. October 13, 2007. [Oral Presentation]
7. **A. R. Golshayan**, S. George, D. Heng, T. Mekhail, T. K. Choueiri, P. Elson, L. Wood, J. A. Garcia, M. Zhou, B. I. Rini, R. M. Bukowski. Metastatic renal cell carcinoma (RCC) with sarcomatoid differentiation treated with VEGF-targeted therapy. The Sixth International Kidney Cancer Symposium. October 13, 2007. [Poster Presentation]
8. **A.R. Golshayan**, D.Y. Heng, S. George, T.K. Choueiri, P. Elson, L.S. Wood, T.M. Mekhail, J.A. Garcia, H. Aydin, M. Zhou, R.M. Bukowski & B.I. Rini. Metastatic Sarcomatoid Renal Cell Carcinoma treated with VEGF-Targeted

- Therapy. 2008 ASCO Genitourinary Cancers Symposium. February 16<sup>th</sup> 2008. [Oral Abstract Presentation]
9. **A.R. Golshayan**, S. George, P. Elson, L.S. Wood, J. A. Garcia, R. M. Bukowski, & B. I. Rini. VEGF-targeted Therapy in metastatic Renal Cell Carcinoma Patients with Renal Insufficiency. 2008 ASCO Genitourinary Cancer Symposium. February 16<sup>th</sup> 2008. [Poster Presentation]
  10. S. George, J. A. Garcia, A. Golshayan, L. Wood, C. Nemec, T. Mekhail, P. Elson, R. M. Bukowski, B. I. Rini. Dose escalation of sorafenib in metastatic renal cell carcinoma (mRCC) patients (pts). 2008 ASCO Genitourinary Cancer Symposium. February 16<sup>th</sup> 2008. [Poster Presentation]
  11. Lagwinski N., Choueiri T.K., **Golshayan A.**, Raghavan D., Hansel D.E. Morphologic and Clinical Features in 41 Patients with Small Cell Carcinoma of the Bladder. USCAP 2008 Annual Meeting. March 1-7, 2008. [Poster Presentation]
  12. **A. R. Golshayan**, S. George, D. Y. Heng, P. Elson, L. Wood, J. A. Garcia, H. Aydin, M. Zhou, R. M. Bukowski, B. I. Rini. Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5102) [Poster Presentation]
  13. **A. R. Golshayan**, P. Elson, L. Wood, J. A. Garcia, R. Dreicer, B. I. Rini. Impact of tumor volume on outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. 2009 ASCO Genitourinary Cancer Symposium. February 26<sup>th</sup> 2009. [Poster Presentation]
  14. D. Y. Heng, D. Y. Heng, W. Xie, M. Regan, M. A. Warren, T. Cheng, S. A. North, J. J. Knox, C. Kollmannsberger, D. F. Mcdermott, **A. R. Golshayan**, B. I. Rini, T. K. Choueiri. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. 2009 ASCO Genitourinary Cancer Symposium. February 26<sup>th</sup> 2009. [Oral Presentation]
  15. **A. R. Golshayan**, P. Elson, L. Wood, J. A. Garcia, R. Dreicer, B. I. Rini. Tumor Burden Characteristics are Associated with Outcomes in Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC) Treated with Sunitinib. 2009 ASCO Symposium. [Poster Discussion]

## *Abstracts*

1. Sekeres MA, Jin T, Maciejewski J, Kalaycio ME, Brown S, Advani A, **Golshayan A**, Sobecks R, Kattan MW. Characterization, resource use, and the economic impact of low-risk myelodysplastic syndrome (MDS) at an MDS specialty center. *Journal of Clinical Oncology*. 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 6098
2. K. Almhanna, **A. Golshayan**, M. Sands, A. Levitin, R. Kim, R. Pelley, S. Kalmadi. Response to trans-arterial chemoembolization prior to orthotopic liver transplantation or hepatic resection in patients with hepatocellular carcinoma. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 15114
3. H. Siddaiah, **A. R. Golshayan**, P. Elson, M. Zhou, J. A. Garcia, R. M. Bukowski, B. I. Rini. Unclassified renal cell carcinoma (RCC): Analysis of clinical and pathologic features. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 16044)
4. S. A. Vaziri, **A. R. Golshayan**, B. I. Rini, H. Aydin, M. Zhou, L. Sercia, L. Wood, M. K. Ganapathi, R. M. Bukowski, R. Ganapathi. The von Hippel Lindau (VHL) gene status is not always identical in paired primary (P) and metastatic (M) lesion in patients with clear cell renal cell carcinoma (CCRCC). *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 16049)
5. D. Y. Heng, P. Elson, **A. R. Golshayan**, M. A. Warren, C. Kollmannsberger, K. N. Chi, T. Cheng, S. A. North, J. A. Garcia, R. M. Bukowski, B. I. Rini. A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 16057)
6. John A. Fortney, M.D., Andrew S. Kraft M.D., **Ali Golshayan M.D.**, Alan Brisendine CCRP, David T. Marshall, M.D. Phase I Trial of Androgen Deprivation, Weekly Docetaxel and Concurrent Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of High-Risk Prostate Adenocarcinoma. Submitted to 2009 ASTRO meeting